Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (With IgE/Body Weight Combinations Above That in the SmPC Dosing Table) to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Omalizumab.
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2011
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2010 Actual end date (August 2008) added as reported by ClinicalTrials.gov.
- 01 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.